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Summary 
Toxic shock syndrome (TSS) is a multi system disorder resulting from superantigen-mediated 
cytokine production. Nearly 90% of the clinical cases of TSS arise  due to an exotoxin, toxic 
shock syndrome toxin-1 (TSST-1), elaborated by toxigenic strains of Staphylococcus aureus.  It is 
clearly established that besides antigen-specific signals a variety of costimulatory signals are re- 
quired for full T  cell activation. However, the nature and potential redundancy of costimula- 
tory signals are incompletely understood, particularly with regards to superantigen-mediated T 
cell activation in vivo. Here we report that CD28-deficient mice (CD28-/-)  are completely 
resistant to TSST-l-induced lethal TSS while CD28  (+/-)  littermate mice were partially re- 
sistant to TSST-1. The mechanism for the resistance of the CD28 (-/-)  mice was a complete 
abrogation of TNF-e~ accumulation in the serum and a nearly complete (90%) impairment of 
IFN-'y secretion in response to TSST-1 injection. In contrast, the serum level oflL-2 was only 
moderately influenced by the variation of CD28 expression. CD28 (-/-)  mice retained semi- 
tivity to TNF-0r as demonstrated by equivalent lethality after cytokine injection. These findings 
establish  an  essential  requirement for CD28  costimulatory signals  in  TSST-l-induced TSS. 
The hierarchy of TSST-1 resistance among CD28  wild-type (CD28+/+),  CD28 heterozy- 
gnus (CD28+/-),  and CD28-/-  mice suggests  a gene-dose effect, implying that the levels 
of T  cell surface CD28 expression critically regulate superantigen-mediated costimulation. Fi- 
nally, as these results demonstrate the primary and non-redundant role of CD28 receptors in 
the initiation of the in vivo cytokine cascade,  they suggest therapeutic approaches for superan- 
tigen-mediated immunopathology. 
T 
oxic shock syndrome (TSS)  is characterized clinically 
by high fever, hypotension, erythroderma, skin desqua- 
mation,  and  in  severe  cases,  multiple  organ  failure  and 
death (1). TSS is induced by a number of bacterial superan- 
tigens  (SAg)  and among these SAgs,  the toxic shock syn- 
drome toxin-1 (TSST-1) is the most common cause ofexo- 
toxin-induced TSS  (1,  2).  TSST-1,  produced by several 
toxigenic  strains  of Staphylococcus  aureus,  binds  to  MHC 
class II molecules on antigen presenting cells (3) and stimu- 
lates V[32-bearing T  cells in humans (4) and V[33-,  V[315-, 
and V[317-bearing T  cells in mice (5, 6). Upon activation, 
these T  cells proliferate and produce a surge of proinflam- 
matory cytokines such as IL2, TNF-ci, and IFN-y (2), and it 
is these cytokines that eventuate in the clinical syndrome (2). 
For conventional antigens to trigger T  cells,  two signals 
are needed: the first signal is delivered by the TCR-Ag-Ia 
complex and the second signal by the interaction between 
a costirnulatory molecule on APC and its  T  cell counter- 
receptor (7-9). Recent observations in vitro also support a 
dependence  on  a  costimulatory signal  for  SAg-mediated 
activation ofT cells (10-13). However, one study has con- 
cluded that SAg-stimulated T  cell proliferation in vitro is 
independent of CD28 (14). Others have concluded that the 
requisite costimulatory signals for nominal antigen and su- 
perantigen may  differ in  studies  using  astrocytes as  APC 
(15).  Together, these data strongly suggest an in vitro re- 
quirement  for  costimulatory  signals  for  TSST-l-induced 
T  cell responses, however in vivo, a requirement for par- 
ticular costimulatory signals  has  not yet been  established. 
To date only one study has addressed the requirement for 
CD28 costimulation in vivo. Muraille and coworkers dem- 
onstrated a partial amelioration with anti-B7-2 antibodies, 
but not anti-B7-1 antibodies in Staphylococcal enterotoxin B 
(SEB)-induced TSS  (16).  Since  the  CD28-mediated  co- 
stimulatory signal is emerging as an important regulator of 
both endogenous and exogenous SAg-induced T  cell re- 
sponses,  CD28-/-  mice were used to assess the require- 
ment  for  CD28  involvement  in  TSST-l-induced  TSS. 
The CD28-/-  mice were entirely resistant to TSST-1- 
induced TSS, providing genetic evidence to indicate that 
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tory signal for TSS. Our results also  demonstrated that dif- 
ferent  levels  of T  cell  CD28  expression  in  CD28+/+, 
CD28+/-  and CD28-/-  mice correlated with TSST-1- 
induced lethality and with  the  serum TNF-ci and IFN-~ 
levels.  Surprisingly,  TSST-l-induced elevation  in  serum 
IL-2 levels were only moderately influenced by CD28 ex- 
pression.  Finally,  injection of TNF-o~  entirely  abolished 
TSST-  1 resistance of CD28-/-  mice, confirming a maj  or 
role of TNF-o~ as an effector in TSS. 
Materials  and Methods 
Mice.  Female C57BL/6 (H-2  u) mice (age 6-8 weeks) were pur- 
chased from The Jackson Laboratory (Bar Harbor, ME). CD28-/- 
mice  were  generated  as  previously  described  (17).  A  male 
CD28+/-  mouse,  as  produced by backcrossing  the  originally 
described  CD28-/-  mice to a C57BL/6 mouse, was bred with 
a  female  C57BL/6  mouse  to  produce  heterozygous  offspring. 
The  heterozygous  litter  mates  were  intercrossed  to  generate 
CD28+/+, CD28+/-  and CD28-/-  mice. These mice were 
further backcrossed to the C57BL/6 background for five genera- 
tions. The mice were phenotyped for CD28 expression by FACS 
analysis of peripheral blood T  cells and genotyped by a poly- 
merase  chain reaction (PCtL)  from genomic DNA obtained by 
tail biopsy using primers specific for either wild-type or knock- 
out CD28  constructs  (17). The mice used as controls were the 
wild-type and heterozygous litter mates  of the  CD28-deficient 
mice. The experiments described herein were conducted accord- 
ing to the principles set forth in the Guide for The Care and Use 
of Laboratory Animals, NIH Publication, 85-23 (1985). 
Determination of CD28 Phenotype by Flow Cytometry.  The  CD28 
phenotype was determined by using a FITC-conjugated  anti-CD3 
mAb (PharMingen, San Diego, CA), a phycoerythrin-conjugated 
anti-CD28 mAb. Background staining levels were determined by 
use of a FITC- or phycoerythrin-conjugated  Leu-4 mAb (Phar- 
Mingen). For phenotyping, peripheral blood was collected from 
(C57BL/6  5<  CD28 KO) F5 mice and PBMC were isolated by 
gradient centrifugation. 106 PBMC were incubated with a FITC- 
conjugated anti-CD3  mAb  followed  by  phycoerythrin-conju- 
gated anti-CD28 mAb. The stained cells were analyzed by an Ep- 
ics flow cytometer (Couker Inc., Hialeah, FL) and an Excel-based 
curve smoothing program was used to describe the histogram. 
Monodonal Antibodies and Reagents.  Fluorochrome-conjugated 
anti-CD3 and anti-CD28 antibodies were procured from Phar- 
Mingen. TSST-1 was purchased from Toxin Technology (Sarasota, 
FL). D-galactosamine (D-Gal) was purchased  from Sigma Chemi- 
cal Co. (St. Louis, MO). 
Mortality Assay.  CD28-deficient mice or their control wild- 
type and heterozygous litter mates were injected with 20 p.g of 
TSST-1 in their hind foot pads 30 rain after intraperitoneal injec- 
tion of D-Gal. 
Sera Preparation.  The CD28-deficient or control mice, 12 in 
each  group, were treated with D-Gal and TSST-1  as described 
above.  Two mice from each  group were euthanized at each  of 
the indicated time-points and their blood was clotted on ice, then 
centrifuged at 10,000  rpm. The superuatants  were collected  and 
stored at -70~  for subsequent lymphokine assays. 
Lymphokine Assay.  Using appropriate dilutions ofsera,  TNF-Ix, 
IL-2,  and IFN-~/ were assayed with Endogen (Cambridge,  MA) 
ELISA kits according to the manufacturer's instructions. 
Statistical Analysis.  Each  experiment was  performed  two  to 
four times and representative  data are presented.  Differences  be- 
tween experimental groups  in the mortality assay were analyzed 
using Fischer's exact test. ELISAs were analyzed using Student's 
t test. 
Results 
The Level of CD28 Expression  Is a Critical Determinant for 
TSST-1-induced Lethal Shock,  To assess the role of the CD28 
costimulatory receptor in TSST-l-induced shock, mice ho- 
mozygous for the disrupted CD28 gene (CD28-/-)  were 
compared to their wild-type homozygous (CD28+/+)  or 
CD28 heterozygous (CD28+/-)  litter mates. These mice 
were  obtained by intercross of mice subsequent to  back- 
cross done five times of the original CD28 heterozygote by 
C57BL/6 strain. The CD28 genotype was defined by PCtk 
against genomic DNA using primers specific for wild-type 
or disrupted CD28  (17)  (data not shown).  In preliminary 
studies, we could not detect differences in the peripheral T 
cell repertoire of the CD28-/-  and CD28+/+  mice as 
determined by flow cytometric analysis of VJ33, V~36, and 
V[38 expressing T  cells (data not shown), confirming previ- 
ous studies that have not revealed CD28-mediated differ- 
ences  in  thymic  selection  for  nominal and  endogenous 
SAgs (17,  18). The phenotypic expression of CD28 on the 
surface of resting T  cells in peripheral blood was assessed by 
flow  cytometric analysis (Fig.  1  a).  It was  found that  the 
surface  staining  with  anti-CD28-PE  of  T  cells  from 
CD28-/-  mice  had  background  fluorescence  intensity 
while  T  cells from  CD28+/+  mice  had  a  much higher 
fluorescence intensity. T  cells from CD28+/-  mice dem- 
onstrated  an  intermediate  staining  intensity  with  anti- 
CD28. These results are consistent with the idea that CD28 
surface expression on T  cells is controlled by a gene-dosage 
effect. 
To  test  the  effect  of  CD28  expression  on  TSST-1- 
induced  lethal  shock,  CD28+/+,  CD28+/-  and 
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Figure  1.  (A)  CD28 expres- 
sion on CD28+/+, CD28+/-, 
and  CD28-/-  mice  after 
breeding  onto  the  C57BL/6 
background as described in Ma- 
terials and Methods. The level of 
CD28 expression on the surface 
of peripheral blood T  cells was 
measured by flow cytometry. (/3) 
TSST-l-induced  mortality  in 
CD28+/+  (circle), CD28+/- 
(triangle) and CD28-/- (square) 
mice. The three groups (n =  6) 
of mice, were presensitized  with 
40  t~g of D-galactosamine intra- 
peritoneaUy 30 rain  before 20 p.g 
injection  of  TSST-1  in  their 
hind foot pads. Mice were ob- 
served for  72  h  to  score the 
TSST-l-induced mortality. Sur- 
vival of the CD28- / -  mice was 
significantly  better than  the 
CD28+/+  mice  (P  =  002, 
Fisher Exact Test). 
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with D-Gal and TSST-1  as described previously (2).  D-Gal 
was used to abolish the natural resistance of the rodents to 
enterotoxins  (2).  All  CD28+/+  mice  showed  signs  of 
TSST-l-induced  illness  including  shivering,  piloerection, 
cessation of movement and heaping up together within 2 h 
of TSST-1  injection.  In striking contrast,  none  of the  six 
CD28-/-  mice tested  showed any sign of illness.  While 
six out of six CD28+/+  mice died within 36 h of TSST-1 
injection, all CD28-/-  mice survived (Fig. 1 b) indicating 
that functional expression of the CD28 gene is required for 
TSST-l-induced TSS.  Interestingly,  CD28+/-  mice dis- 
played an intermediate  pattern  of disease  susceptibihty  and 
showed a delayed death--of the six mice injected, four died 
and  two  survived  (Fig.  1  b).  These  mice  also  developed 
symptoms from TSS later,  with  onset ~4  h  after TSST-1 
injection.  This  pattern  of CD28-dependent  TSSTq-resis- 
tance was reproduced in four independent experiments. Since 
CD28+/-  mice have intermediate  T  cell surface expres- 
sion of CD28 between  CD28+/+  and CD28-/-  mice, 
the level of CD28 expression hkely determined the severity 
of symptoms and clinical course of the disease.  It has been 
shown that CTLA4, a related molecule that shares the same 
ligands  with  CD28  (19),  is  expressed  in  CD28-/-  mice 
(20).  The  association  between  CD28  expression  and 
TSST-1 lethahty indicated that B7:CTLA4 interactions are 
not sufficient for the induction of TSS. 
Secretion  of Proinflammatory  Cytokines  Is Dependent  on  the 
Level of CD28 Expression.  It has been shown previously that 
a cytokine cascade mediates the immunopathology of TSS. 
Therefore,  the role of CD28 in cytokine production, par- 
ticularly TNF-ci, IFN-',/, and IL-2 production during TSS 
was assessed (Fig. 2  a).  Serum levels of TNF-{x were mea- 
sured at multiple time points after TSST-1 injection. While 
a sharp increase was observed within 1 h after TSST-1 injec- 
tion in CD28+/+  mice, CD28-/-  mice had a profound 
defect in TNF-e~ serum levels, The complete abrogation of 
TNF-c~ accumulation at all  time points in the CD28-/- 
mice was in contrast to the level of TNF-oL in CD28+/- 
mice that was nearly half of that observed in CD28+/+  mice 
(Fig. 2 a).  Given the intermediate level of CD28 expression 
in these mice, these results indicate that the level of CD28 
expression  determines  the  level  of TNF-o~  secretion  after 
TSST-1 injection. 
IFN-y is also known to be involved in the acute inflam- 
mation  and tissue  damage  characteristic  of TSS pathology 
and  therefore,  serum  levels  of  IFN-~/  from  TSST-1- 
injected mice were examined  (Fig. 2  b).  In contrast to the 
early accumulation of TNF-cq the appearance of IFN-~/in 
the  serum was delayed.  CD28+/+  mice displayed a pro- 
nounced rise in the serum level of IFN-~/4 h after TSST-1 
injection, whereas only a marginal elevation of IFN-~/was 
observed in CD28-/-  mice. Similar to TNF-eq CD28+/- 
mice  displayed  intermediate  IFN-y levels,  indicating  that 
the  level  of CD28  expression  also  determined  TSST-1- 
induced IFN-'r production. 
Previous  reports  indicated  that  CD28  can  provide  co- 
stimulation for SEB to result in increased  IL-2 gene tran- 
scription in vitro (10).  Consistent with this, serum IL-2 el- 
evation in vivo was significantly lower in CD28-/-  mice 
as  compared  to  CD28+/+  and  CD28+/-  mice  after 
TSST-1 injection (Fig. 2 c). In contrast to the CD28 gene- 
dosage differences shown above for TNF-ot and to a lesser 
extent for IFN-~/production, the level of IL-2 in CD28+/- 
mice  was  not  different  from  that  found  in  CD28+/+ 
mice.  Apparently  low-level  CD28  expression  is  sufficient 
for full IL-2 secretion while the higher CD28 levels found 
in CD28+/+  mice are required  for full TNF-a.  Further- 
more,  the  reduced  but  still  appreciable  IL-2  elevation  in 
the CD28-/-  mice indicates the presence of CD28-inde- 
pendent mechanisms of costimulation for IL-2, in contrast 
to an absolute requirement for CD28 in the case of TNF-~ 
(Fig. 2, a vs c). 
TNF-ee Is an Essential Cytokine Required for TSST-1-Induced 
Shock Syndrome.  TNF-(x has been proposed to be a major 
cytokine in TSS as it is the first cytokine to peak after TSST-1 
injection, it effects the subsequent production of other cy- 
tokines  and  their  receptors,  and  anti-TNF-a  antibodies 
prevent  TNF-induced  lethality  (2).  Thus,  the  TSST-1- 
resistant  phenotype  of the  CD28-/-  mice  could be  ex- 
plained  by the  lack  of TNF-o~  secretion.  Alternatively,  it 
was  possible  that  the  downstream  cascade  of TNF-medi- 
ated events was also disrupted in the CD28-/-  mice, and 
therefore, that CD28-/-  mice might be resistant to TNF-0c 
To distinguish between these possibilities,  TNF-o~ was in- 
jected at a sublethal dose along with TSST-1 in CD28+/+ 
and CD28-/-  mice.  As shown in Fig. 3  a,  the TSST-1- 
resistant  CD28-/-  mice  succumb  to  TSST-l-induced 
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Figure 2.  Serum concentrations of TNF-oL (A), 
IFN-y (/3), and IL-2 (C) at different time points af- 
ter  injection of TSST-1  in  CD28+/+  (circle), 
CD28+/- (square),  and CD28-/- (triangle)  mice. 
These mice, 12 in each group, were treated with 
D-galactosamine and TSST-1 as described in Fig. 1. 
Two mice from each group were euthanized at 
each of the indicated time-points and the sera were 
collected and stored at -70~  for subsequent cy- 
tokine assay. The cytoldnes were assayed by ELISA 
(Endogen, Inc., Boston, MA) and the mean value 
from the paired sera depicted. TSS when TSST-1 was accompanied by a sublethal dose of 
TNF-ot.  Neither  reagent  alone  reproduced  the  lethal  ef- 
fects of TSS in CD28-/-  mice. 
The  TNF-ot  add-back  experiment  in  the  CD28-defi- 
cient  mice  was  used  to  determine  whether  the  TSS  that 
occurred in these  mice was  associated with  reconstitution 
of IFN-y secretion.  Wild type  or CD28-/-  mice were 
injected with TSST-1 with or without TNF-tx as described 
above and sera were collected 4  h  after TSST-1  injection, 
based upon the expected kinetics determined in Fig 2. IFN-~/ 
levels  were  about  threefold  lower  in  normal  mice  given 
TNF-c~  injections  as  compared  to  TSST-1  injection. 
CD28-/-  mice given TSST-1  only had levels sevenfold 
less  than  wild-type  mice.  It  was  found  that  TNF--~  co- 
injection  with  TSST-1  restored  the  levels  of IFN-y  in 
CD28-/-  mice  nearly  to  the  level  of CD28+/+  mice 
treated with TSST-1  (Fig. 3 b). Thus, conditions associated 
with  eventual  lethality  had  high  IFN-y levels  while  the 
conditions associated with ultimate survival had lower IFN-',/ 
levels.  These results are consistent with the notion that the 
lethal  effect  of TNF-oe  as  observed  in  TSS  is  mediated 
through  induction  of cytokines including  IFN-y.  There- 
fore we concluded that CD28-transduced signals are essen- 
tial  for production  of TNF-ot  in  the  context  of TSST-1 
stimulation and further, that TNF-c~ can bypass the CD28- 
mediated  signaling  deficit  to  reconstitute  the  clinical  fea- 
tures of TSS in CD28-/-  mice. 
Discussion 
Since costimulation through CD28 plays a critical role in 
a variety of T  cell responses against nominal foreign antigens, 
auto-, allo-, or xeno-geneic transplantation antigens (9,  18, 
21), we have studied the role of this costimulatory signal in 
superantigen-driven  T  cell activation by using CD28-/- 
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Figure 3.  (A) Role of TNF-cl 
in  TSST-l-induced  mortality. 
CD28+/+ (square) and CD28-/- 
(circle)  mice were injected with 
D-galactosamine and/or  TSST-1 
as described in Fig. 1. The mice 
also received a sublethal dose of 
rTNF-ot  (1  rig/mouse) intrave- 
nously. The  control groups re- 
ceived only rTNF4x at the same 
dose (triangle).  (B) Effect  of  TNF-et 
injection on serum IFN-y con- 
centration. Groups of ~rfice were 
treated as in  (A), and  sera ob- 
tained 4 h after TSST-1 injection 
to  measure IFN-y  by  ELLS& 
The mean and  range of paired 
serum samples is indicated. 
mice. The concordance of the level ofT cell surface CD28 
expression  with  the  severity and lethality  of TSS  confirm 
the pivotal role of the CD28 molecule in TSST-l-induced 
TSS.  The  CD28-/-  mice  had  a  striking  defect  in  the 
ability  to secrete  TNF-0~,  and reveal  that  there  are no re- 
dundant costimulatory molecules for this form of superan- 
tigen-mediated T  cell activation. Furthermore, serum levels 
of TNF4x and IFN-y were also observed to be correlated 
to the CD28 surface expression and lethality. 
The pathogenesis of TSS by bacterial SAg is mediated by 
T  cells  as SCID mice are entirely resistant to TSST-1  and 
SEB but are rendered susceptible when reconstituted  with 
syngeneic  T  cells  (2,  22).  The  T  cells  which  express  the 
SAg-reactive V[3  TCRs,  e.g.,  V[33,  V[315,  and  V[317  for 
TSST-1,  V~8  for SEB  are required  for the  onset of TSS. 
Although  SAg can bind  directly  the  MHC  class  II mole- 
cules  and  activate  the  pertinent  VI3  TCR-bearing  T  ceils 
by direct interactions with TCR, recent studies have dem- 
onstrated that ICAM-l-deficient mice are resistant to SEB- 
induced lethal  TSS  (23),  indicating the  importance  of ad- 
hesion molecules in TSS. Therefore, it is now evident that 
in addition to MHC class II, TCR  and adhesion molecules, 
costimulatory molecules also play important roles in  SAg- 
induced T  cell responses. 
The  most likely  explanation  uncovered  for the  TSST- 
1-resistant phenotype of the  CD28-deficient mice was the 
impairment of TNF-~x secretion. It is notable that while the 
serum  levels  of TNF-ot  and  IFN-~/  in  TSST-l-injected 
CD28+/-  mice  were  almost  half the  level  of those  in 
CD28+/+  mice,  the  IL-2  levels  were  not  different  be- 
tween  CD28+/+  and  +/-  mice.  Three  different possi- 
bilities may account for this difference in TNF4x and IL-2 
regulation.  First, the threshold of CD28-mediated signaling 
required  for the  production  of these  cytokines may differ 
and thus,  signaling through V~-TCR  and  engagement  of 
fewer CD28  molecules  on T  cells  would be sufficient for 
triggering  IL-2 but  not  TNF-c~  and  IFN-y.  The  second 
possible mechanism would involve CD28-mediated stabili- 
zation  of cytokine  mRNA  (24).  Since  TNF-e~  is  tran- 
scribed at a substantial rate in resting T  ceils  (25)  but steady 
state mRNA levels of TNF-o~ remain low due to rapid de- 
gradation  (26),  it  is  possible  that  CD28  signaling  may be 
more  important  for stabilizing  TNF-~x  mRNA  than  IL-2 
mRNA  (24).  Finally, it is possible that CD28 has effects at 
a posttranslational level. There are two forms of tumor ne- 
crosis factor, a type II membrane protein of relative molec- 
ular mass 26 kD and a soluble,  17-kD form generated from 
the cell-bound protein by metalloproteinase-mediated pro- 
teolytic  cleavage.  Inhibition  of the  metalloproteinase  pro- 
tects mice from endotoxic shock (27, 28).  It is possible that 
the activity of this enzyme which has been shown to be es- 
sential  for  the  release  of TNF-ot  from its  precursor  is  in 
some manner  regulated  by CD28.  Further  studies  will  be 
required to define the mechanism of the TNF-ot defect in 
CD28-deficient mice. 
Our results confirm previous studies using other experi- 
mental approaches  indicating that  TNF-ci  appears  to be  a 
major cytokine in TSS because not only is it the first cyto- 
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self-amplifying cascade of cytokine interactions  that  even- 
tuates  in  a  lethal  outcome  (2,  22).  The  cascade may start 
with TNF-oL which stimulates T  cell IL-2 receptor expres- 
sion and thereby, confers IL-2 responsiveness to result in an 
enhanced  T  cell proliferation  (29).  In support  of this,  we 
have found that the T  cells from CD28-/-  mice prolifer- 
ate much less in response to TSST-1  than the T  cells from 
CD28+/§  mice.  This low T  cell proliferation can be re- 
stored by TNF-ci and is sensitive to anti-IL2 receptor anti- 
body (data  not shown).  Thus,  although  CD28-/-  mice 
have significant levels of IL-2 in response to stimulation by 
nominal antigen as shown by Lucas and coworkers (18) and 
as shown here after SAg stimulation, the T  cells may not be 
fully responsive due to low IL2-receptor expression result- 
ing from the  absence  of TNF-ci  (data  not shown).  How- 
ever,  after  being  induced  by TNF-oL, IFN-%  in its  turn, 
signals through TNF-Ix-induced IFN-'y receptors on mac- 
rophages  to  augment MHC  class  II expression  (30).  This 
may  effect  a  more  ef/icient  presentation  of TSST-1  to 
T  cells as T  cell proliferation is known to be directly pro- 
portional to the product of antigen concentration and the 
density ofla molecules (31). The primary role of TNF-ci in 
TSS is also supported by studies indicating that neutralizing 
TNF-0~ in vivo by injection of anti-TNF-cx antibody also 
rescues  mice  from  TSST-l-induced  death  (2)  and  that 
TNF-oL receptor (p55) knock out mice are entirely resistant 
to SEB-induced TSS (32). 
In  conclusion,  CD28  is  essential  for  TSST-1  induced 
TNF-ct  production  and  the  subsequent  fatal  pathological 
sequelae.  Disruption of CD28 gene abrogates TNF-oL pro- 
duction  and  thereby  prevents  the  onset  of the  syndrome. 
Therefore,  knowing  that  the  CD28-mediated  costimula- 
tory signal is non-redundant  for T  cell  superantigens  pro- 
vides  a  rationale  for  novel  therapeutic  interventions  for 
toxic  shock  syndrome  and  potentially  for  other  states  of 
immunopathology caused by dysregulation  of T  cell lym- 
phokine secretion. 
We thank Richard Hodes for review of  the manuscript, and Rhonda Germond and Doug Smoot for techni- 
cal assistance. 
Supported by Naval Medical Research  and Development (NMRDC) grant no. 61152N AC.0001.001.1406. 
The views expressed in this article are those of the authors and do not reflect the official policy or position of 
the Department of the Navy, Department of Defense, nor the United States Government. 
Address correspondence  to Ryo Abe,  Mail Stop  061, Naval  Medical  Research Institute,  8091 Wisconsin 
Ave., Bethesda, MD 20889-5607. 
Received for publication 2January  1996 and in revised  form  12 April 1996. 
ReFerences 
1. Chatila,  T., P. Scholl, N. Ramesh, N. Trede, R. Fuleihan,  T. 
Morio, and R.S. Geha. 1992. Cellular  and molecular mecha- 
nisms of immune activation by microbial superantigens:  stud- 
ies using toxic shock syndrome toxin-.  Chem. Immunol. 55: 
146-171. 
2.  Miethke, T., K. Duschek, C. Wahl, K. Heeg, and H. Wag- 
ner.  1993.  Pathogenesis  of the toxic shock syndrome: T  cell 
mediated lethal  shock caused by the  superantigen  TSST-1. 
Eur. J. Immunol. 23:1494-1500. 
3.  Uchiyama,  T.,  T.  Tadakuma,  K.  Imanishi,  M.  Araake,  S. 
Saito,  X.J. Yan, H. Fujikawa,  H. Igarashi, and N. Yamaura. 
1989. Activation of murine T  cells by toxic shock syndrome 
toxin-1.  The  toxin-binding structures  expressed  on murine 
accessory cells are MHC class II molecules.J.  Immunol. 143: 
3175-3182. 
4.  Choi, Y., J.A. Lafferty, J.R. Clements, J.K. Todd, E.W. Gel- 
fand, J. Kappler,  P. Marrack,  and B.L.  Kotzin.  1990.  Selec- 
tive  expansion of T  cells expressing  V beta 2 in toxic shock 
syndrome.J. Exp. Meal. 172:981-984. 
5.  Norton, S.D., P.M. Schlievert,  R.P. Novick, and M.K. Jen- 
kins.  1990.  Molecular requirements for T  cell activation by 
the staphylococcal toxic shock syndrome toxin-l.J. Immunol. 
144:2089-2095. 
6.  Marrack,  P.,  and J.  Kappler.  1990.  The  staphylococcal en- 
terotoxins  and their relatives. Science (Wash. DC). 248:705-711. 
7.  Schwartz,  R.H. 1990. A cell culture model for T lymphocyte 
clonal anergy. Science (Wash. DC). 248:1349-1356. 
8. June, C.H., J.A. Bluestone, L.M. Nadler, and C.B. Thomp- 
son.  1994. The B7 and CD28 receptor families. Immunol. To- 
day. 15:321-331. 
9. Boussiotis, V.A., J.G. Gribben, G.J. Freeman, and L.M. Nad- 
ler.  1994.  Blockade of the CD28 co-stimulatory pathway: a 
means to induce tolerance.  Curt. Opin. Immunol. 6:797-807. 
Fraser, J.D., M.E.  Newton, and A. Weiss.  1992.  CD28 and 
T cell antigen receptor signal transduction coordinately regu- 
late interleukin 2 gene expression  in response to superantigen 
stimulation.J.  Exp. Med. 175:1131-1134. 
Goldbach Mansky, R., P.D.  King, A.P. Taylor, and B. Du- 
pont. 1992. A co-stimulatory role for CD28 in the activation 
of CD4+  T  lymphocytes by staphylococcal enterotoxin B. 
Int. Immunol. 4:1351-1360. 
Green, J.M.,  L.A.  Turka,  C.H. June,  and C.B.  Thompson. 
1992. CD28 and staphylococcal enterotoxins synergize to in- 
duce MHC-independent  T-cell proliferation.  Cell Immunol. 
145:11-20. 
Ohnishi,  H.,  T.  Tanaka, J.  Takahara,  and M.  Kotb.  1993. 
CD28 delivers costimulatory signals for superantigen-induced 
activation of antigen-presenting cell-depleted human T lym- 
10. 
11. 
12. 
13. 
2679  Saha et al.  Brief Definitive Report phocytes.J, lmmunol.  150:3207-3214. 
14. Damle,  N.K.,  K.  Klussman,  G.  Leytze,  and  P.S.  Linsley. 
1993.  Proliferation of human T  lymphocytes induced with 
superantigens  is  not  dependent  on  costimulation  by  the 
CD28 counter-receptor B7.J. Immunol. 150:726-735. 
15. R.ott, O., U. Tontsch, and B. Fleischer. 1993. Dissociation of 
antigen-presenting  capacity of astrocytes for peptide-antigens 
versus superantigens.J. Immunol. 150:87-95. 
16. Muraille, E., T. De Smedt, J. Urbain, M. Moser,  and O. Leo. 
1995. B7.2 provides  co-stimulatory functions in vivo in re- 
sponse to staphylococcal  enterotoxin B. Eur. J.  Immunol. 25: 
2111-2114. 
17. Shahinian, A., K. Pfeffer, K.P. Lee, T.M. Kundig, K. Kishi- 
hara, A. Wakeham, K. Kawai, P.S. Ohashi,  C.B. Thompson, 
and T.W. Mak.  1993. Differential  T  cell costimulatory re- 
quirements in CD28-deficient mice. Science (Wash. DC). 261: 
609-612. 
18. Lucas, P.J.,  I. Negishi, K. Nakayama,  L.E.  Fields, and D.Y. 
Loh.  1995. Naive CD28-deficient T cells can initiate but not 
sustain an in vitro antigen-specific immune response. J.  Im- 
munoI. 154:5757-5768. 
19. Linsley,  P.S.,  W.  Brady,  M.  Urnes,  L.S. Grosmaire,  N.K. 
Damle, andJ.A. Ledbetter.  1991. CTLA-4 is a second recep- 
tor for the B  cell activation antigen 37. J.  Exp.  Med.  174: 
561-569. 
20. Walunas, T.L.,  D.J.  Lenschow,  C.Y.  Bakker,  P.S.  Linsley, 
G.J. Freeman, J.M.  Green, C.B.  Thompson, and J.A.  Blue- 
stone.  1994. CTLA-4 can function as a negative regulator of 
T cell activation.  Immunity.  1:405-413. 
21. Harlan, D.M., R. Abe, K.P. Lee, and C.H. June. 1995. Po- 
tential roles of the B7 and CD28 receptor families in autoim- 
munity and immune evasion.  Clin. Immunol. Immunopathol. 
75:99-111. 
22. Miethke, T., C. Wahl, K. Heeg, B. Echtenacher, P.H. Kram- 
mer, and H. Wagner. 1992. T cell-mediated lethal shock trig- 
gered in mice by the superantigen staphylococcal enterotoxin 
B: critical role of tumor necrosis factor._/. Exp. Med. 175:91-94. 
23. Xu, H., J.A. Gonzalo, Y. St. Pierre, I.P,. Williams, T.S. Kupper, 
P,.S. Cotran, T.A. Springer, andJ.C. Gutierrez-Ramos. 1994. 
Leukocytosis and resistance to septic shock in intercellular ad- 
hesion molecule l-deficient mice.J. Exp. Med.  180:95-109. 
24. Lindsten, T., C.H. June, J.A. Ledbetter,  G. Stella, and C.B. 
Thompson.  1989. Regulation  of  lymphokine  messenger 
RNA stability by a surface-mediated  T  cell activation path- 
way. Science (Wash. DC). 244:339-343. 
25. Jongeneel, C.V., A.N. Shakhov,  S.A. Nedospasov,  and J.C. 
Cerottini. 1989. Molecular control of tissue-specific expres- 
sion at the mouse TNF locus. Eur.J. Immunol. 19:549-552. 
26. Beutler, B., and A. Cerami. 1989. The biology of cachectin/ 
TNF--a primary mediator of the host response. Annu.  Rev. 
Immunol. 7:625-655. 
27. Gearing, A.J., P. Beckett,  M. Christodoulou, M. Churchill, J. 
Clements, A.H.  Davidson, A.H.  Drummond, W.A.  Gallo- 
way,  1k.  Gilbert, and J.L.  Gordon.  1994. Processing  of tu- 
mour necrosis  factor-alpha  precursor by metalloproteinases. 
Nature (Loud.) 370:555-557. 
28. Mohler, K.M., P.P,.  Sleath, J.N.  Fitzner, D.P.  Cerretti, M. 
Alderson,  S.S. Kerwar,  D.S.  Torrance, C.  Otten-Evans, T. 
Greenstreet,  and K. Weerawarna. 1994. Protection against a 
lethal  dose of endotoxin by an inhibitor of tumour necrosis 
factor processing. Nature (Lamd.). 370:218-22(3. 
29. Pimentel Muinos,  F.X.,  M.A.  Munoz  Fernandez, and  M. 
Fresno.  1994. Control of T  lymphocyte activation and IL-2 
receptor expression  by endogenously secreted  lymphokines. 
J. Immunol. 152:5714-5~722. 
30. Steeg,  P.S.,  IL.N.  Moore,  H.M. Johnson,  and J.J. Oppen- 
helm.  1982. Regulation of murine macrophage  la  antigen 
expression by a lymphokine with immune interferon activity. 
j. Exp.  Med.  156:1780-1793. 
31. Matis, L.A., L.H.  Glimcher, W.E. Paul, and IL.H. Schwartz. 
1983. Magnitude of response  of histocompatibility-restricted 
T-cell clones  is a function of the product of the concentra- 
tions of antigen and Ia molecules.  Proc. Natl. Acad. Sci. USA. 
80:6019-6023. 
32. Jongeneel,  C.V.,  A.N.  Shakhov,  S.A. Nedospasov,  J.C. 
Cerottini, K. Pfeffer, T. Matsuyama, T.M. Kundig, A. Wake- 
ham, K. Kishihara, A. Shahinian et al. 1993. Molecular con- 
trol  of tissue-specific  expression  at  the  mouse  TNF  locus. 
Mice deficient for the 55 kd tumor necrosis factor  receptor 
are resistant to endotoxic shock, yet succumb to L. monocy- 
togenes infection. Cell. 73:457-467. 
2680  Toxic Shock-resistant Phenotype of CD28-deficient Mice 